Every person's cancer is unique.

A growing tumour is made up of many different cancer cells. If a cancer is malignant, a select population of cancer cells can escape the tumour mass and invade the blood stream. When this happens, the cancer is at a turning point. Escapee cancer cells in the blood stream can travel to another site in the body and grow a second tumour at a later stage, called a metastasis. These escapee cancer cells in the blood are called Circulating Tumour Cells, abbreviated as ‘CTCs.’


Escapee cancer cells in the blood can be found by a simple blood test.

A CTC Count finds existing escapee CTCs in a blood sample and counts them. A CTC count every 3-6 months can be used to monitor the effectiveness of cancer treatment and assess changes in aggressiveness. This test is the best way of closely monitoring the status of a person's cancer.

A CTC Count finds existing escapee CTCs in a blood sample and counts them. A CTC count every 3-6 months can be used to monitor the effectiveness of cancer treatment and assess changes in aggressiveness. This test is the best way of closely monitoring the status of a person's cancer.

This test exposes a person's CTCs to recommended chemotherapy or botanical cancer killing agents, as selected by healthcare practitioners. This test is to see which therapy or therapy combination is most effective at killing a person's CTCs. CTCs that survive exposure are said to be resistant while CTCs that are killed by exposure are said to be sensitive. Cancer treatment can then be tailored to target the cells that are responsible for cancer spread.

This test exposes a person's CTCs to recommended chemotherapy or botanical cancer killing agents, as selected by healthcare practitioners. This test is to see which therapy or therapy combination is most effective at killing a person's CTCs. CTCs that survive exposure are said to be resistant while CTCs that are killed by exposure are said to be sensitive. Cancer treatment can then be tailored to target the cells that are responsible for cancer spread.

Companion Diagnostics identifies the presence of receptors on a person's CTCs that may be specifically targeted by certain cancer treatments. Practitioners can also choose to test for other 'biomarkers' that indicate important factors, such as aggression and activity. This test helps practitioners select treatments to target the unique nature of each person's cancer.

Companion Diagnostics identifies the presence of receptors on a person's CTCs that may be specifically targeted by certain cancer treatments. Practitioners can also choose to test for other 'biomarkers' that indicate important factors, such as aggression and activity. This test helps practitioners select treatments to target the unique nature of each person's cancer.

Tumour Sphere Units tests to see if a person's CTCS can multiply to form microscopic clusters, called Tumour Sphere Units in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis.

Tumour Sphere Units tests to see if a person's CTCS can multiply to form microscopic clusters, called Tumour Sphere Units in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis.